Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Erin M Bange

Showing results (1-10 of 21) with videos related to

Pageof 3
Sort By:
JAMA Network Open|April 15, 2025
Time Toxicity of Clinical Trials-Better Than FearedErin M Bange, John K Lin
JCO Oncology Practice|September 17, 2020
Reply to J. Warner-Cohen et alErin M Bange, Kim A Reiss, Ronac Mamtani
JAMA Oncology|October 28, 2021
Immunotherapy Adverse EffectsTimothy J Brown, Ronac Mamtani, Erin M Bange
BMJ Quality & Safety|May 18, 2021
Implementing automated prognostic models to inform palliative care: more than just the algorithmErin M Bange, Katherine R Courtright, Ravi B Parikh
JAMA Network Open|December 9, 2025
Time Toxicity of Cancer Care-A Call to ActionSahil D Doshi, Jeffrey A Rappaport, Erin M Bange
Cancer Journal (Sudbury, Mass.)|January 24, 2024
Telemedicine and Cancer Care: Barriers and Strategies to Optimize DeliverySahil D Doshi, Erin M Bange, Bobby Daly, et al.
NEJM Catalyst Innovations in Care Delivery|March 13, 2026
Opportunities for Home Cancer Care: The Final FrontierSahil D Doshi, Charlotte D Malling, Kristen McNiff Landrum, et al.
JNCI Cancer Spectrum|October 16, 2024
The feasibility and acceptability of home phlebotomy for patients with cancerErin M Bange, Camila Bernal, Kemi Bolutayo Gaffney, et al.
JAMA Network Open|August 29, 2022
Accuracy of a Text Intervention to Minimize the Burden of Cancer Care Among Patients Treated With Immune Checkpoint InhibitorsErin M Bange, Kerry Coughlin, Wenrui Li, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 9, 2021
Carfilzomib-Induced Atypical Hemolytic Uremic Syndrome in a Patient With Heterozygous CFHR3/CFHR1 Deletion Treated With EculizumabCraig W Freyer, Erin M Bange, Sarah Skuli, et al.
Pageof 3

Showing results (1-10 of 21) with videos related to

Sort By:
Pageof 3
JAMA Network Open|April 15, 2025
Time Toxicity of Clinical Trials-Better Than FearedErin M Bange, John K Lin
JCO Oncology Practice|September 17, 2020
Reply to J. Warner-Cohen et alErin M Bange, Kim A Reiss, Ronac Mamtani
JAMA Oncology|October 28, 2021
Immunotherapy Adverse EffectsTimothy J Brown, Ronac Mamtani, Erin M Bange
BMJ Quality & Safety|May 18, 2021
Implementing automated prognostic models to inform palliative care: more than just the algorithmErin M Bange, Katherine R Courtright, Ravi B Parikh
JAMA Network Open|December 9, 2025
Time Toxicity of Cancer Care-A Call to ActionSahil D Doshi, Jeffrey A Rappaport, Erin M Bange
Cancer Journal (Sudbury, Mass.)|January 24, 2024
Telemedicine and Cancer Care: Barriers and Strategies to Optimize DeliverySahil D Doshi, Erin M Bange, Bobby Daly, et al.
NEJM Catalyst Innovations in Care Delivery|March 13, 2026
Opportunities for Home Cancer Care: The Final FrontierSahil D Doshi, Charlotte D Malling, Kristen McNiff Landrum, et al.
JNCI Cancer Spectrum|October 16, 2024
The feasibility and acceptability of home phlebotomy for patients with cancerErin M Bange, Camila Bernal, Kemi Bolutayo Gaffney, et al.
JAMA Network Open|August 29, 2022
Accuracy of a Text Intervention to Minimize the Burden of Cancer Care Among Patients Treated With Immune Checkpoint InhibitorsErin M Bange, Kerry Coughlin, Wenrui Li, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 9, 2021
Carfilzomib-Induced Atypical Hemolytic Uremic Syndrome in a Patient With Heterozygous CFHR3/CFHR1 Deletion Treated With EculizumabCraig W Freyer, Erin M Bange, Sarah Skuli, et al.
Pageof 3